IMRX Reports 17.3 Month Median OS, 36% ORR, 82% DCR in Phase 2a Atebimetinib Trial for Pancreatic Cancer
Immuneering Corporation Class A Common Stock · PHARMACEUTICAL PREPARATIONS · Now $5.77
+1.1% in 1h after detection
Post-detection moves
1h
+1.1%
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS